Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00376259 · ClinicalTrials.gov registry record · Phase 3
Study of Combination Therapy With LdT Plus Adefovir Versus Adefovir Alone
A Phase 3 study, sponsored by Novartis.
- Terminated
- Registry status
- Phase 3
- Development phase
- 43
- Enrollment target
NCT00376259 is a Phase 3 study that was terminated before completion, run by Novartis. The registered enrollment target is 43 participants.
The verdict
NCT00376259, a Phase 3 study, was terminated before completion, sponsored by Novartis.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 43 participants
- Enrollment target
Study Summary
This study is being conducted to compare the safety and effectiveness of the investigational medication LdT (telbivudine) used in combination with adefovir dipivoxil (a drug currently approved by the Food and Drug Administration \[FDA\] for the treatment of hepatitis B virus \[HBV\]) versus adefovir dipivoxil used alone. The results for patients taking the combination therapy will be compared to the results for patients taking adefovir alone.
Interventions
- DRUG telbivudine
- DRUG adefovir dipivoxil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2007-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00376259
The ClinicalTrials.gov registry entry for NCT00376259 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis, which has 265 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which telbivudine is the first listed.
NCT00376259 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00376259 about?
NCT00376259 is a clinical study titled "Study of Combination Therapy With LdT Plus Adefovir Versus Adefovir Alone". This study is being conducted to compare the safety and effectiveness of the investigational medication LdT (telbivudine) used in combination with adefovir dipivoxil (a drug currently approved by the Food and Drug Administration \[FDA\] for the treatment of hepatitis B virus \[HBV\]) versus adefovir...
What is the current status of trial NCT00376259?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 43 participants. The study started on 2007-01.
What interventions are being tested in trial NCT00376259?
The interventions under investigation include: telbivudine (DRUG), adefovir dipivoxil (DRUG).
Who is sponsoring clinical trial NCT00376259?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.